VYNE Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David T. Domzalski
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- P.O. Box 125 Stewartsville NJ United States of America 08807
- IPO Date
- Jan 25, 2018
- CIK
- 0001566044
- Website
- vynetherapeutics.com
- Similar Companies
- Business
- VYNE Therapeutics Inc. (Nasdaq: VYNE) is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immunological conditions with high unmet medical needs. The company leverages its proprietary InhiBET platform to advance novel BET inhibitors, including its lead product candidate repibresib gel (VYN201), a topically administered pan-bromodomain and extra-terminal (BET) inhibitor soft drug designed for diseases involving diverse inflammatory cell signaling pathways with low systemic exposure, primarily targeting nonsegmental vitiligo; and VYN202, an oral BD2-selective small molecule BET inhibitor in Phase 1b trials for acute control and chronic management of immune-mediated inflammatory conditions such as moderate-to-severe plaque psoriasis. VYNE operates in the biotechnology sector, serving patients with autoimmune and immuno-inflammatory diseases through innovative topical and oral formulations. Founded in 2003 and headquartered in Bridgewater, New Jersey, the company conducts its clinical programs primarily in the United States. In recent developments, VYNE initiated a strategic review in August 2025 to explore options including partnerships, licensing, mergers, acquisitions, and asset sales to maximize shareholder value, engaging LifeSci Capital as financial advisor; the Phase 2b trial of repibresib gel in vitiligo missed primary endpoints, prompting trial termination and a search for an external development partner; and the FDA partially lifted a clinical hold on VYN202, enabling female enrollment while requiring additional toxicology data for males. Previously known as Menlo Therapeutics Inc., VYNE changed its name in September 2020 to reflect its focus on innovative immuno-inflammatory therapies.
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Savara (NASDAQ:SVRA) vs. VYNE Therapeutics (NASDAQ:VYNE) Critical Comparison
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
VYNE Therapeutics Provides Update on VYN202 Program